For Healthcare Professionals

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

clipboard-pencil

About the study

The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Male and female subjects aged 18 and 65 years with clinical diagnosis of LGMD2I/R9 and confirmation of FKRP gene mutation.
  2. Ability to ascend 4 stairs between 2.5 and 10 seconds.
  3. Ability to walk/run 10 meters in < 30 seconds.
  4. Able to understand and comply with all study procedures.
  5. Sexually active females of childbearing potential and female and male partners of male subjects receiving AB-1003 must use a barrier method of contraception for the first 6 months after dosing.

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Significant cardiomyopathy as defined by echocardiogram (left ventricular ejection fraction <40%), evidence of conduction defect (increased PR and RR intervals, left bundle branch block and QTcF >480m/sec), NYHA Class 3 or 4 heart failure, or MRI gadolinium enhancement evidence of clinically important myocardial fibrosis.
  2. Contraindication to MRI or hypersensitivity to contrast dyes, shellfish or iodine.
  3. Implanted spinal rods, cardiac pacemaker or other implantation that would distort cardiac MRI images.
  4. History of chronic liver disease (e.g. hepatitis, HIV, steatosis) or abnormal liver function (abnormal GGT and/or abnormal total/direct bilirubin and/or AST and ALT >2 ULN).
  5. Abnormal renal function (GFR < 60 ml/min, using the MDRD equation).
  6. Any life-threatening disease, including malignant neoplasms and medical history or malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).
  7. In the opinion of the investigator, a pre-existing medical condition that predisposes the subject to risks that outweighs the potential benefits.
  8. Requirement for daytime ventilatory support.
  9. Change in glucocorticosteroid treatment within 3 months prior to baseline visit.
  10. Exposure to another investigational drug within 3 months prior to study treatment or any previous treatment with gene therapy.
  11. Ongoing participation in any other therapeutic clinical trial.
  12. Neutralizing antibody titer to AAV9 ≥ 1:5.
  13. Female subjects who are pregnant, plan to become pregnant in the next 12 months, or breastfeeding.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 919-561-6210Email iconEmail Study Center

Study Details


Contition

Limb Girdle Muscular Dystrophy,Limb-Girdle Muscular Dystrophy Type 2,LGMD2I,Muscular Dystrophy,LGMD2,LGMD,FKRP,FKRP Mutation,Fukutin Related Protein

Age

18 - 65

Phase

PHASE1/PHASE2

Participants Needed

10

Est. Completion Date

Dec 31, 2028

Treatment Type

INTERVENTIONAL


Sponsor

Asklepios Biopharmaceutical, Inc.

ClinicalTrials.gov NCT Identifier

NCT05230459

Study Number

LION-CS101

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.